Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Yi Ban,Junhua Mai,Xin Li,Marisa Mitchell-Flack,Tuo Zhang,Lixing Zhang,Lotfi Chouchane,Mauro Ferrari,Haifa Shen,Xiaojing Ma

DOI: https://doi.org/10.1158/0008-5472.22412618.v1

2023-01-01

Abstract:This table contains patient clinical data and auto rejection rates of 4T1 tumors.

What problem does this paper attempt to address?

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Data from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Yi Ban,Junhua Mai,Xin Li,Marisa Mitchell-Flack,Tuo Zhang,Lixing Zhang,Lotfi Chouchane,Mauro Ferrari,Haifa Shen,Xiaojing Ma

DOI: https://doi.org/10.1158/0008-5472.c.6508478

2023-01-01

Abstract:AbstractThe tumor-promoting potential of CCL5 has been proposed but remains poorly understood. We demonstrate here that an autocrine CCL5–CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. The absence of the autocrine CCL5 abrogated the generation of granulocytic myeloid-derived suppressor cells and tumor-associated macrophages. In parallel, enhanced maturation of intratumoral neutrophils and macrophages occurred in spite of tumor-derived CCL5. The refractory nature of ccl5-null myeloid precursors to tumor-derived CCL5 was attributable to their persistent lack of membrane-bound CCR5. The changes in the ccl5-null myeloid compartment subsequently resulted in increased tumor-infiltrating cytotoxic CD8+ T cells and decreased regulatory T cells in tumor-draining lymph nodes. An analysis of human triple-negative breast cancer specimens demonstrated an inverse correlation between "immune CCR5" levels and the maturation status of tumor-infiltrating neutrophils as well as 5-year-survival rates. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities. Our study suggests that the myeloid CCL5–CCR5 axis is an excellent target for cancer immunotherapy. Cancer Res; 77(11); 2857–68. ©2017 AACR.
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy

Wei Chen,Hui Shi,Zhuojun Liu,Fan Yang,Jia Liu,Leqiang Zhang,Yajin Wu,Yuanshi Xia,Yuxuan Ou,Ruiting Li,Ting Zhang,Jiecheng Zhang,Xiaoyan Ke,Kai Hu,Jian Yu

DOI: https://doi.org/10.1158/1078-0432.22489906.v1

2023-01-01

Abstract:Supplementary table 6
Table S3 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan,Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

DOI: https://doi.org/10.1158/1078-0432.22472418.v1

2023-01-01

Abstract:Supplementary Table S3: Adverse Events
Table S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan,Li,Wen Wang,Bin-Shen OuYang,Shu Cheng,Li Wang,Wen Wu,Peng-Peng Xu,Muharrem Muftuoglu,Ming Hao,Su Yang,Mu-Chen Zhang,Zhong Zheng,James Li,Wei-Li Zhao

DOI: https://doi.org/10.1158/1078-0432.22472421.v1

2023-01-01

Abstract:Supplementary Table S2: Amount and potency of CAR T cells
Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen,Zohreh Amoozgar,Xin Liu,Shuichi Aoki,Zelong Liu,Sarah M. Shin,Aya Matsui,Alexei Hernandez,Zhangya Pu,Stefan Halvorsen,Pin-Ji Lei,Meenal Datta,Lingling Zhu,Zhiping Ruan,Lei Shi,Daniel Staiculescu,Koetsu Inoue,Lance L. Munn,Dai Fukumura,Peigen Huang,Slim Sassi,Nabeel Bardeesy,Won Jin Ho,Rakesh K. Jain,Dan G. Duda

DOI: https://doi.org/10.1158/2326-6066.25523060.v1

2024-01-01

Abstract:Supplementary Table S3: IMC panel.
Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Jiefei Han,Jianchun Duan,Hua Bai,Yuqi Wang,Rui Wan,Xin Wang,Si Chen,Yanhua Tian,Di Wang,Kailun Fei,Zhuoran Yao,Shuhang Wang,Zhimin Lu,Zhijie Wang,Jie Wang

DOI: https://doi.org/10.1158/2326-6066.22543056.v1

2023-01-01

Abstract:Baseline characteristics of patients in the exploratory group (discovery set and validation set) and the control group.
Supplementary Table 1 from CD155T/TIGIT Signaling Regulates CD8<sup>+</sup> T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer

Weiling He,Hui Zhang,Fang Han,Xinlin Chen,Run Lin,Wei Wang,Haibo Qiu,Zhuang Zhang,Ling Qi,Weijing Zhang,Qinbo Cai,Yongmei Cui,Wenting Jiang,Han Wang,Zunfu Ke

DOI: https://doi.org/10.1158/0008-5472.22415936.v1

2023-01-01

Abstract:Supplementary Table 1 shows clinicopathological characteristics of the patients studies in this project.
Supplementary Methods, Tables 1 - 2, Figure Legend from Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions Via Reverse Hepatocellular Carcinoma–Induced Immune Suppression

Xiaodong Sun,Qiangjun Sui,Cai Zhang,Zhigang Tian,Jian Zhang

DOI: https://doi.org/10.1158/1535-7163.22501288

2023-01-01

Abstract:PDF file - 130K, Supplementary Table 1 Fluorochrome-conjugated antibodies used in flow cytometry.; Supplementary Table 2 Primers used in PCR.
Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Jiefei Han,Jianchun Duan,Hua Bai,Yuqi Wang,Rui Wan,Xin Wang,Si Chen,Yanhua Tian,Di Wang,Kailun Fei,Zhuoran Yao,Shuhang Wang,Zhimin Lu,Zhijie Wang,Jie Wang

DOI: https://doi.org/10.1158/2326-6066.22543059.v1

2023-01-01

Abstract:Univariable and multivariable analysis of progression-free survival (PFS).
Supplementary Table 1 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Jian Ye,Weihua Guo,Chongkai Wang,Colt A. Egelston,Massimo D'Apuzzo,Geereesh Shankar,Marwan G. Fakih,Peter P. Lee

DOI: https://doi.org/10.1158/2767-9764.24298820.v1

2023-01-01

Abstract:Detailed summary of CRC specimens and patient overall survival.
Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399923.v1

2023-01-01

Abstract:<p>PDF file - 71KB, Supplementary Table 1 Characteristics of 7 types of cancer patient in cancer survey array. Supplementary Table 2 Characteristics of patient in melanoma RNA chip. Supplementary Table 3 Characteristics of patient in melanoma IHC chip. Supplementary Table 4. Characteristics of patient in flow cytometry analysis.</p>
Supplementary Table S1 from the Tumor-Suppressive Function of UNC5D and Its Repressed Expression in Renal Cell Carcinoma

Dan Lu,Dong,Yu Zhou,Min Lu,Xue-Wen Pang,Yan Li,Xiao-Jun Tian,Yu Zhang,Jun Zhang

DOI: https://doi.org/10.1158/1078-0432.22450682.v1

2023-01-01

Abstract:Supplementary Table S1 - PDF file 84K, Supplementary Table S1. Primers and oligonucleotides used in this study
Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384287.v1

2023-01-01

Abstract:Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674252

2023-01-01

Abstract:Supplementary Table S3: ## Raw count matrix of the RNA-seq data. ## Atg5-KO vs Ctrl-KO (Veh).
Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384281.v1

2023-01-01

Abstract:Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Supplementary Table 1 from ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients

Brian J. Wilson,Tobias Schatton,Qian Zhan,Martin Gasser,Jie Ma,Karim R. Saab,Robin Schanche,Ana-Maria Waaga-Gasser,Jason S. Gold,Qin Huang,George F. Murphy,Markus H. Frank,Natasha Y. Frank

DOI: https://doi.org/10.1158/0008-5472.22387731

2023-01-01

Abstract:Supplementary Table 1 from ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients
Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384284.v1

2023-01-01

Abstract:Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Tables from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Data from Targeting Autocrine CCL5–CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy

Table S3 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Table S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Supplementary Table S3 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Supplementary Table 1 from CD155T/TIGIT Signaling Regulates CD8&lt;sup&gt;+&lt;/sup&gt; T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer

Supplementary Methods, Tables 1 - 2, Figure Legend from Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions Via Reverse Hepatocellular Carcinoma–Induced Immune Suppression

Supplementary Table S2 from TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Supplementary Table 1 from Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver Versus Lung Metastases

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Table S1 from the Tumor-Suppressive Function of UNC5D and Its Repressed Expression in Renal Cell Carcinoma

Supplementary Table 1 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 1 from ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 1 from CD155T/TIGIT Signaling Regulates CD8<sup>+</sup> T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer